Discovery of AZD8165 – a clinical candidate from a novel series of neutral thrombin inhibitors

A novel series of neutral thrombin inhibitors has been developed using a selection process based on docking experiments and property calculations and predictions. This work resulted in the identification of the highly potent thrombin inhibitor compound 85 (Ki = 300 pM) and the corresponding propionate prodrug 5 (AZD8165) as a candidate for clinical evaluation in the treatment of thrombosis and related diseases. AZD8165 was found to be safe and well tolerated and delivered the expected pharmacological response in a phase I trial in healthy male volunteers.

[1]  Staffan Karlsson,et al.  A One-Pot Asymmetric Synthesis of a N-Acylated 4,5-Dihydropyrazole, A Key Intermediate of Thrombin Inhibitor AZD8165 , 2014 .

[2]  H. Zachrisson,et al.  Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations. , 2014, Bioorganic & medicinal chemistry letters.

[3]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[4]  Alexander Hillisch,et al.  Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? , 2011, Angewandte Chemie.

[5]  S. Pehrsson,et al.  Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats , 2010, Thrombosis and Haemostasis.

[6]  B. Tomczuk,et al.  Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif. , 2010, Journal of medicinal chemistry.

[7]  Bengt I Eriksson,et al.  Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement , 2008, Thrombosis and Haemostasis.

[8]  V. Matassa,et al.  Design and Discovery of Novel, Potent Pyrazinone-Based Thrombin Inhibitors with a Solubilizing P1-P2-Linker , 2006 .

[9]  Udo E W Lange,et al.  Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. , 2006, Bioorganic & medicinal chemistry letters.

[10]  B. Eriksson,et al.  Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement , 2005, Journal of clinical pharmacology.

[11]  Lawrence C Kuo,et al.  Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors. , 2004, Journal of medicinal chemistry.

[12]  C. Lindemann,et al.  Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs. , 2004, International journal of pharmaceutics.

[13]  N. Bunnett,et al.  Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.

[14]  Youwei Yan,et al.  Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides. , 2003, Bioorganic & medicinal chemistry letters.

[15]  U. Bredberg,et al.  Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Youwei Yan,et al.  Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. , 2003, Bioorganic & medicinal chemistry letters.

[17]  H. Nar,et al.  Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.

[18]  M. Nishida,et al.  The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. , 2001, The Journal of clinical investigation.

[19]  C. Masimirembwa,et al.  In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. , 2001, Combinatorial chemistry & high throughput screening.

[20]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[21]  C. Masimirembwa,et al.  Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[22]  S. Lee,et al.  Fluorobenzamidrazone thrombin inhibitors: influence of fluorine on enhancing oral absorption. , 1999, Bioorganic & medicinal chemistry letters.

[23]  S. Brady,et al.  Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. , 1998, Journal of medicinal chemistry.

[24]  S. Brady,et al.  Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. , 1998, Journal of medicinal chemistry.